These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39194669)

  • 1. Surgery Combined with Local Implantation of Doxorubicin-Functionalized Hydroxyapatite Halts Tumor Growth and Prevents Bone Destruction in an Aggressive Osteosarcoma.
    Liu Y; Corbascio T; Huang J; Engellau J; Lidgren L; Tägil M; Raina DB
    J Funct Biomater; 2024 Aug; 15(8):. PubMed ID: 39194669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral: A trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin.
    Liu Y; Nadeem A; Sebastian S; Olsson MA; Wai SN; Styring E; Engellau J; Isaksson H; Tägil M; Lidgren L; Raina DB
    Mater Today Bio; 2022 Mar; 14():100227. PubMed ID: 35265825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma.
    Liu Y; Raina DB; Sebastian S; Nagesh H; Isaksson H; Engellau J; Lidgren L; Tägil M
    Acta Biomater; 2021 Sep; 131():555-571. PubMed ID: 34271171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal
    Liu Y; Sebastian S; Huang J; Corbascio T; Engellau J; Lidgren L; Tägil M; Raina DB
    Front Bioeng Biotechnol; 2022; 10():1076320. PubMed ID: 36601389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ Co-Delivery of Doxorubicin and Cisplatin by Injectable Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment.
    Si M; Xia Y; Cong M; Wang D; Hou Y; Ma H
    Int J Nanomedicine; 2022; 17():1309-1322. PubMed ID: 35345787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
    Qiu R; Sun D; Bai Y; Li J; Wang L
    Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma.
    Feng S; Wu ZX; Zhao Z; Liu J; Sun K; Guo C; Wang H; Wu Z
    ACS Appl Mater Interfaces; 2019 Feb; 11(7):7357-7368. PubMed ID: 30682240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of a biomaterial-based anticancer drug delivery system as an alternative to conventional post-surgery bone cancer treatment.
    Bischoff I; Tsaryk R; Chai F; Fürst R; Kirkpatrick CJ; Unger RE
    Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():115-124. PubMed ID: 30274043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
    Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
    Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
    Wu NF; Yamamoto J; Aoki Y; Masaki N; Samonte C; Wu J; Bouvet M; Hoffman RM
    Anticancer Res; 2021 Oct; 41(10):4715-4718. PubMed ID: 34593419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
    Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
    J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway.
    Liang C; Yu X; Xiong N; Zhang Z; Sun Z; Dong Y
    Front Oncol; 2020; 10():615146. PubMed ID: 33659212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zeolitic Imidazolate Framework (ZIF-8) Decorated Iron Oxide Nanoparticles Loaded Doxorubicin Hydrochloride for Osteosarcoma Treatment - in vitro and in vivo Preclinical Studies.
    Wu W; Yu X; Sun J; Han Y; Ma Y; Zhang G; Ma Q; Li Q; Xiang H
    Int J Nanomedicine; 2023; 18():7985-7999. PubMed ID: 38164268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid decorated metal-organic frameworks loaded with doxorubicin for tumor-targeted chemotherapy of osteosarcoma.
    Xu W; Lou Y; Chen W; Kang Y
    Biomed Tech (Berl); 2020 Apr; 65(2):229-236. PubMed ID: 31605575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
    Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
    Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Black phosphorus quantum dots camouflaged with platelet-osteosarcoma hybrid membrane and doxorubicin for combined therapy of osteosarcoma.
    Xu Y; Du L; Han B; Wang Y; Fei J; Xia K; Zhai Y; Yu Z
    J Nanobiotechnology; 2023 Jul; 21(1):243. PubMed ID: 37507707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
    Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
    Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ethylene glycol)-sheddable reduction-sensitive polyurethane micelles for triggered intracellular drug delivery for osteosarcoma treatment.
    Yang Z; Guo Q; Cai Y; Zhu X; Zhu C; Li Y; Li B
    J Orthop Translat; 2020 Mar; 21():57-65. PubMed ID: 32099805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.